Praktické lékárenství – 4/2019

www.praktickelekarenstvi.cz e37 AKTUÁLNÍ FARMAKOTERAPIE KORTIKOIDY – LÉČBA PRVNÍ VOLBY U CIDP? PRAKTICKÉ LÉKÁRENSTVÍ Giannini F, Sabatelli M, IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropahty: a randomised controlled trial. Lancet Neurol 2012; 11: 493–502. 13. Pourmand R. Immune-mediated neuromuscular diseases. Basel: Karger, 2009. 14. Rabin M, Mutlu G, Stojkovic T, Maisonobe T, Lenglet T, Fournier E, Bouche P, Leger JM, Viala K. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factor associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psy- chiatry 2014; 85: 899–904. 15. Sommer C. Therapie akuter und chronischer immunvermittelter Neuropathien und Neuritiden. Deutsche Gesselschaft für Neurologie. Leitlinien für Diagnostik und Therapie in der Neurologie Aufl. 5, 2012.www.dgn.org 16. Vallat JM, Sommer C, Magy L. Chronic demyelinating polyradiculoneuropathy: dia- gnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402–412. 17. Van Schaik IN, Eftimov F, van Doorn PE. Pulsed high dose dexamethasone treatment versus standard prednisolone treatment in chronic inflammatory demyelinating poly- radiculoneuropathy (CIDP): a double blind randomized controlled clinical trial (PREDICT study). Lancet Neurol 2010; 9: 245–253. 18. Yoon MS, Chan A, Gold R. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disor 2011; 4: 193–200.